REGN Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) is expected to report earnings on October 29, 2026, before the market open. The consensus earnings estimate is $12.89 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +14.5% since its last earnings release on July 30, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals Inc is a fully integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Sector
Healthcare
Industry
Biotechnology